Latest News and Press Releases

Positive Phase 3 HERIZON-GEA-01 results for Ziihera® (zanidatamab-hrii) in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) presented at ASCO GI Up to $440.0 million in milestone...

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million, to support Teva’s anti-IL-15 candidate,...

Day One today announced the release of preliminary 2025 OJEMDA™ net product revenue and provides 2026 net product revenue guidance

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million to support Teva’s anti-IL-15 candidate...

Phase 1/2a study with lead Radio-DARPin MP0712 initiated; first patient dosing expected Q1 2026, initial data anticipated in 2026Full imaging and dosimetry data from MP0712 compassionate care program...

MIAMI, FL, Jan. 10, 2026 (GLOBE NEWSWIRE) -- Why Consumers Are Researching Ozempatch Ingredients in 2026 OzemPatches, also promoted under the name Rejuvacare Ozempatch, is a topical herbal...

RALEIGH, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) -- La estrategia de crecimiento de Attindas Hygiene Partners dio hoy un importante paso hacia adelante con la adquisición de Societá Italiana...

RALEIGH, North Carolina, Jan. 10, 2026 (GLOBE NEWSWIRE) --  Strategi pertumbuhan Attindas Hygiene Partners mencapai satu pencapaian penting hari ini melalui pengambilalihan Società Italiana...

RALEIGH, North Carolina, Jan. 10, 2026 (GLOBE NEWSWIRE) -- Die Wachstumsstrategie von Attindas Hygiene Partners hat heute mit der Übernahme von Società Italiana Lavorazione Cellulosa (SILC S.p.A.)...

北卡羅來納州羅利, Jan. 10, 2026 (GLOBE NEWSWIRE) --  Attindas Hygiene Partners 今天收購 Società Italiana Lavorazione Cellulosa (SILC S.p.A.)，標誌其增長策略邁出重要一步。Attindas 已與 SILC 簽立股份購買協議，將這間 53 年歷史的家族企業收歸旗下。 SILC...